Journal: Artificial cells, nanomedicine, and biotechnology

Article Title: Integrated bioinformatics analysis of miRNA expression in Ewing sarcoma and potential regulatory effects of miR-21 via targeting ALCAM/CD166.

doi: 10.1080/21691401.2019.1620760

Figure Lengend Snippet: Figure 11. (A) Schematic diagram of luciferase reporter assay. The green dots represent stronger fluorescence signal, the blue dots represent weak fluorescence sig- nal. (B) Relative luciferase activity of indicated ALCAM reporter constructs in 293 T cells. Transfection of miR-21 suppressed the activity of the luciferase reporter which contained the 30-UTR of ALCAM significantly but did not influence the luciferase activity of the mutated 30-UTR structure in 293 T cells. p < .01. (C) Microscopic observation of hMSC cell line, A673 cell line and 293 T cells.

Article Snippet: Cell lines and cell culture The human Ewing sarcoma cell lines A673 SK-ES-1 RD-ES and the hMSC cell line was obtained from the American Type Culture Collection (ATCC).

Techniques: Luciferase, Reporter Assay, Fluorescence, Activity Assay, Construct, Transfection

Journal: bioRxiv

Article Title: Trabectedin Enhances Oncolytic Virotherapy by Reducing Barriers to Virus Spread and Cytotoxic Immunity in Preclinical Pediatric Bone Sarcoma

doi: 10.1101/2024.03.02.582994

Figure Lengend Snippet: oHSV+trabectedin synergizes to increase the disease control rate and reduce tumor burden in human xenograft models. The best response for each treated tumor through 28 days, the average tumor burden, and spider plots tracking individual tumor volumes over the full study period are shown for A) CHLA-258 (Ewing sarcoma), B) EW5 (Ewing sarcoma), C) PDX-0027 (rhabdomyosarcoma), D) A673 (Ewing sarcoma), and E) A673 in NSG-SGM3 NK-deficient mice (lack T, B, and NK cells). PBS and oHSV (1.0 x 107 pfu) were given i.Tu. on Days 0 & 2. Trabectedin (0.15 mg/kg) was given I.V. on Days 0 & 7. Statistical analyses of the disease control rates (CR+PR+SD) were performed using a pairwise Fisher’s exact test with p values adjusted using the Benjamini-Hochberg procedure; *p < 0.05, **p < 0.01, ***p < 0.001. Summarized data with error bars depict mean ± SEM.

Article Snippet: The A673 human Ewing sarcoma cell line (Cat# CCL-81), Vero green monkey kidney cell line (Cat# CRL-1598), and K7M2 mouse osteosarcoma cell line (Cat# CRL-2836) were purchased from the American Type Culture Collection (ATCC) (Manassas, VA).

Techniques: Control

Journal: bioRxiv

Article Title: Trabectedin Enhances Oncolytic Virotherapy by Reducing Barriers to Virus Spread and Cytotoxic Immunity in Preclinical Pediatric Bone Sarcoma

doi: 10.1101/2024.03.02.582994

Figure Lengend Snippet: Trabectedin increases viral spread and decreases antiviral gene expression in immunodeficient Ewing sarcoma models. A) Treatment schema for scRNAseq tumor collection: PBS and oHSV (1.0 x 10 pfu) were given i.Tu. on Days 0 & 2, trabectedin (0.15 mg/kg) was given I.V. on Day 0, and scRNAseq samples were collected on Day 3 to ensure sufficient cell viability for sequencing. B) oHSV viral titer (pfu) from A673 tumors treated with a single dose of oHSV or oHSV+trabectedin. C) UMAP plots of oHSV transcript presence in all tumor cells, split by treatment group. D) Violin plot of the expression level (log-transformed) of all oHSV transcripts for all tumor cells in each treatment group. E) Expression level of HSV time-dependent gene modules shown as a feature plot (UMAP) for all tumor cells and split by treatment groups that contained oHSV. A relative expression cutoff of 1 minimized color skewing by high expressing outlier cells and maintained color scale consistency between feature plots. F) Violin plot of the expression level (log-transformed) of HSV time-dependent gene modules for all tumor cells in treatment groups that contained oHSV. G) Results from gene set enrichment analysis showing the running enrichment score for the “Herpes simplex virus 1 infection” pathway, which represents the intrinsic cellular response to HSV-1. Gene set enrichment analysis was performed on a gene list which was ranked by the gene expression fold change (log2FC) calculated for tumor cells treated with oHSV+trabectedin compared to those treated with oHSV monotherapy. The schema displays the top genes with enrichment changes from the “Herpes simplex virus 1 infection” pathway.

Article Snippet: The A673 human Ewing sarcoma cell line (Cat# CCL-81), Vero green monkey kidney cell line (Cat# CRL-1598), and K7M2 mouse osteosarcoma cell line (Cat# CRL-2836) were purchased from the American Type Culture Collection (ATCC) (Manassas, VA).

Techniques: Gene Expression, Sequencing, Expressing, Transformation Assay, Virus, Infection